431 related articles for article (PubMed ID: 20823833)
1. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
Aoki Y; Nakamura A; Yokota T; Saito T; Okazawa H; Nagata T; Takeda S
Mol Ther; 2010 Nov; 18(11):1995-2005. PubMed ID: 20823833
[TBL] [Abstract][Full Text] [Related]
2. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
3. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
8. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
9. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
10. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
Aoki Y; Yokota T; Nagata T; Nakamura A; Tanihata J; Saito T; Duguez SM; Nagaraju K; Hoffman EP; Partridge T; Takeda S
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13763-8. PubMed ID: 22869723
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
12. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974
[TBL] [Abstract][Full Text] [Related]
13. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
[TBL] [Abstract][Full Text] [Related]
16. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
17. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
Cao L; Han G; Gu B; Yin H
PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
[TBL] [Abstract][Full Text] [Related]
18. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
19. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]